SEATTLE, Aug. 28, 2017 (GLOBE NEWSWIRE) -- Cascadian Therapeutics, Inc. (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced posters on tucatinib in multiple tumor types will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress being held September 8-12, 2017 in Madrid, Spain.
Please visit the Cascadian Therapeutics booth #270 at ESMO for more information about tucatinib, the Company’s lead product candidate for the treatment of HER2-positive breast cancer being evaluated in a global, randomized pivotal trial known as HER2CLIMB. Abstracts will be available online at http://www.esmo.org/Conferences/ESMO-2017-Congress/Abstracts. Poster presentations will be available at www.cascadianrx.com as of the presentation date.
Poster Presentations
Title: Progression-free survival and site of first progression in HER2-positive metastatic breast cancer patients with or without brain metastases: A pooled analysis of tucatinib phase I studies
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 264, Location: Hall 8
Title: Tucatinib, a HER2 selective kinase inhibitor, is active in patient derived xenograft (PDX) models of HER2-amplified colorectal, esophageal and gastric cancers
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 1639, Location: Hall 8
Title: Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine in patients with advanced HER2-positive metastatic breast cancer from a phase 1b study
Date: Monday, September 11, 2017, 1:15-2:15 p.m. CEST
Poster: 297, Location: Hall 8
About Tucatinib
Tucatinib is an investigational, orally bioavailable, potent tyrosine kinase inhibitor that is highly selective for HER2 without inhibition of the EGFR. Inhibition of EGFR has been associated with clinically relevant toxicities, including skin rash and diarrhea. Tucatinib has shown activity as a single agent and in combination with both chemotherapy and other HER2 directed agents such as trastuzumab and T-DM1.1,2 Studies of tucatinib in these combinations have shown activity both systemically and in brain metastases. HER2 is a growth factor receptor that is overexpressed in multiple cancers, including breast, ovarian and gastric cancers. HER2 mediates cell growth, differentiation and survival. Tumors that overexpress HER2 (HER2-positive) are more aggressive and historically have been associated with poor overall survival, compared with HER2-negative cancers.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Its lead product candidate, tucatinib, is an investigational oral, selective small molecule HER2 inhibitor. Cascadian Therapeutics is conducting a randomized, double-blind, controlled pivotal clinical trial called HER2CLIMB, which is comparing tucatinib vs. placebo, each in combination with capecitabine and trastuzumab, in patients with locally advanced or metastatic HER2-positive breast cancer with and without brain metastases, who have previously been treated with trastuzumab, pertuzumab and T-DM1. Additional details on HER2CLIMB can be found at www.HER2CLIMB.com or www.clinicaltrials.gov. For more information, please visit www.cascadianrx.com.
References:
- Moulder, S. et al., Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2-Positive Metastatic Breast Cancer. Clin Cancer Res, May 2017.
- Hamilton, E. et al., Efficacy of a Phase 1b Study of Tucatinib (ONT-380), an Oral HER2-Specific Inhibitor, in Combination with Capecitabine and Trastuzumab in HER2-Positive Metastatic Breast Cancer, Including Patients with Brain Metastases. Presented at the San Antonio Breast Cancer Symposium (SABCS) Annual Meeting 2016, San Antonio, TX, December 9, 2016 (Poster P4-21-01).